ENOV ENOVIS CORPORATION

Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability

Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability

Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert

Wilmington, DE, Aug. 19, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, proudly unveils its Scandinavian Total Ankle Replacement (STAR® Ankle), now with new e+™ Polyethylene. Recent U.S. Food and Drug Administration (FDA) approval makes STAR® Ankle the first and only mobile bearing ankle system with e+™ Polyethylene in the United States.1 The implant’s new vitamin E-blended e+™ Polyethylene insert will offer improved durability, stability, and longevity.1

"With e+™ Polyethylene, we uphold our commitment to the advancement of our total ankle portfolio, merging full oxidative resistance with the time-tested design of the STAR® Ankle,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “Building upon the proven success of the STAR® Ankle epitomizes our culture of advancing foot and ankle solutions and elevating patient treatment options. We don't just set the standard—we redefine it.”

e+™ Polyethylene contains the free radical-neutralizing antioxidant vitamin E; as a result, the material resists oxidation and maintains consistent wear rates and stable mechanical properties over time. In contrast, other highly crosslinked polyethylenes are remelted during manufacturing to neutralize free radicals2, a process that can reduce their mechanical strength by up to 12%.1,3

“After extensive clinical experience with this superior material in knee and shoulder implants, along with years of laboratory testing, I expect improved patient outcomes through increased polyethylene longevity. This builds on the outstanding STAR® Ankle long-term metal-component survival rates seen in multiple clinical studies,” stated Dr. Gregory Lundeen, a foot and ankle orthopedic surgeon at Reno Orthopedic Center.

Combined with the recent release of STAR Patient Specific Instrumentation (PSI), the STAR+ Experience represents Enovis’ commitment to continuous improvement, aimed at enhancing patient satisfaction and outcomes. The integration of e+™ Polyethylene in the STAR® Ankle continues to enhance the remarkable success of this implant, which has been used globally over 40,000 times across its 37-year history.4

For more information about the STAR® Ankle with e+™ Polyethylene and Enovis' innovative foot and ankle solutions, please visit .

Individual results may vary. Neither Enovis™ Corporation nor any of its subsidiaries dispense medical advice. The contents of this release do not constitute medical, legal, or any other type of professional advice. Rather, please consult your healthcare professional for information on the courses of treatment, if any, which may be appropriate for you.

Dr. Gregory Lundeen is a consultant for Enovis™ Corporation.

References

  1. e+ testing data on file. Bench test results not necessarily indicative of clinical performance.
  2. Jennings et al. The influence of femoral condylar lift-off on the wear of artificial knee joints. Proc Inst Mech Eng [H]. 2007 Apr;221(3):305-14.
  3. S.M. Kurtz. “The UHMWPE Handbook: Ultra-high Molecular Weight Polyethylene in Total Joint Replacement”. Elsevier Academic Press, 2009.
  4. Enovis® internal document: Includes world-wide implantations of all generations; newest generation has over 40,000 world-wide from 1998-2022



About Enovis

Enovis™ Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .

Media Contact

Diana Aldermae

Enovis Foot & Ankle

MK-10554

Attachment



EN
19/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health,...

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solution...

 PRESS RELEASE

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Ca...

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Eno...

 PRESS RELEASE

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Confer...

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website () at...

 PRESS RELEASE

Enovis Appoints Oliver Engert as Chief Administrative Officer

Enovis Appoints Oliver Engert as Chief Administrative Officer Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis’ strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, “Oliver’s appoi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch